ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1495

Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project

Maria Carmen Garcia-Gomez1, Maria Auxiliadora Martin2, Santos Castañeda3, Fernando Sánchez-Alonso4, Miren Uriarte Ecenarro5, Carlos González-Juanatey6, Romera-Baures Monserrat7, Santos-Rey Jose8, Jose A Pinto-Tasende9, Estefania QuesadaMasachs10, Jesús Tornero11, Olga Martínez González12, Tatiana Cobo-Ibáñez13, Eugenio Chamizo Carmona14, Sara Manrique-Arija15, Dolores Fábregas-Canales16, Federico Díaz-González17, Javier Llorca18, Miguel Angel González-Gay19 and CARMA Collaborative Group, 1Rheumatology, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, 2Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, 3Rheumatology, Hospital de la Princesa, IIS-IP, Madrid, Spain, 4Research Unit of Spanish Society of Rheumatology, Madrid, Spain, 5Donostia University Hospital, San Sebastian, Spain, 6Division or Cardiology, Hospital Lusus Augusti, Lugo, Spain, 7Rheumatology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat (Barcelona), Spain, 8Rheumatology, Hospital Virgen de la Salud, Toledo, Spain, 9Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), A Coruna, Spain, 10Rheumatology, Hospital Universitari Vall d’Hebron, Barcelona, Spain, 11Rheumatology Department, Hospital Universitario Guadalajara, Guadalajara, Spain, 12Rheumatology, HOSPITAL CLÍNICO UNIVERSITARIO DE SALAMANCA, Salamanca, Spain, 13Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, 14Rheumatology, Hospital de Mérida, Mérida, Spain, 15Rheumatology, Hospital Carlos Haya, Malaga, Spain, 16Rheumatology, Hospital de Barbastro, Barbastro (Huesca), Spain, 17Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, 18Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, 19Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, University of Cantabria, Santander, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biologics, Cardiovascular disease, Lipids, rheumatoid arthritis (RA) and tocilizumab

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 14, 2016

Session Title: Rheumatoid Arthritis – Clinical Aspects - Poster II: Co-morbidities and Complications

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Plasma concentrations of lipoprotein (a) [Lp(a)], a lipoprotein with proatherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as rheumatoid arthritis (RA) (1). There are few studies that evaluate the impact of biologic therapies on Lp(a) in RA (2), taking into account that with these new therapies a better control of inflammation is achieved.This study evaluate the plasma concentrations of Lp(a) in Spanish RA patients on biological therapies attending rheumatology outpatient clinics.

Methods: Baseline analysis of the CARMA project (CARdiovascular in rheuMAtology), a 10-year prospective study evaluating the risk of cardiovascular events in RA patients and other forms of inflammatory arthritis who attended rheumatology outpatient clinics at 67 hospitals in Spain. RA patients were classified into four categories: no biologic therapy, undergoing anti-TNF therapy, receiving anti-IL-6 receptor tocilizumab (TCZ), and other biologic therapies (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was biologic therapy. The model was adjusted for confounding factors.

Results: Seven hundred and seventy-five RA patients were analyzed. Total cholesterol and triglycerides concentrations were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index (TC/HDL-c) between TCZ-treated patients and patients without biological therapy was found. After adjusting for confounding factors, patients treated with biologic therapy had lower plasma concentrations of Lp(a) than those not undergoing biologic therapy. However, only TCZ-treated patients achieved statistically significant differences when compared with those not undergoing biologic therapy (β-coefficient: -0.303, 95% confidence interval: -0.558 to -0.047; p=0.02).

Conclusion: RA patients treated with tocilizumab, an inhibitor of interleukin 6 receptor, show lower plasma concentrations of Lp (a) compared to patients without biological therapy.


Disclosure: M. C. Garcia-Gomez, None; M. A. Martin, None; S. Castañeda, None; F. Sánchez-Alonso, None; M. Uriarte Ecenarro, None; C. González-Juanatey, None; R. B. Monserrat, None; S. R. Jose, None; J. A. Pinto-Tasende, None; E. QuesadaMasachs, None; J. Tornero, None; O. Martínez González, None; T. Cobo-Ibáñez, None; E. Chamizo Carmona, None; S. Manrique-Arija, None; D. Fábregas-Canales, None; F. Díaz-González, None; J. Llorca, None; M. A. González-Gay, None.

To cite this abstract in AMA style:

Garcia-Gomez MC, Martin MA, Castañeda S, Sánchez-Alonso F, Uriarte Ecenarro M, González-Juanatey C, Monserrat RB, Jose SR, Pinto-Tasende JA, QuesadaMasachs E, Tornero J, Martínez González O, Cobo-Ibáñez T, Chamizo Carmona E, Manrique-Arija S, Fábregas-Canales D, Díaz-González F, Llorca J, González-Gay MA. Lipoprotein(a) Concentrations in Rheumatoid Arthritis on Biologic Therapy: Results from the Cardiovascular in Rheumatology [CARMA] Study Project [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/lipoproteina-concentrations-in-rheumatoid-arthritis-on-biologic-therapy-results-from-the-cardiovascular-in-rheumatology-carma-study-project/. Accessed April 17, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lipoproteina-concentrations-in-rheumatoid-arthritis-on-biologic-therapy-results-from-the-cardiovascular-in-rheumatology-carma-study-project/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.